

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096878 A9

(51) International Patent Classification:
C12N 15/67 (2006.01)

(21) International Application Number:
PCT/US2024/054033

(22) International Filing Date:
01 November 2024 (01.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/595,753 02 November 2023 (02.11.2023) US
63/611,092 15 December 2023 (15.12.2023) US
63/654,928 31 May 2024 (31.05.2024) US
63/708,529 17 October 2024 (17.10.2024) US

(71) Applicant: **CAPSTAN THERAPEUTICS, INC.**
[US/US]; 9880 Campus Point Drive, Suite 220, San Diego,
CA 92121 (US).

(72) Inventors: **MATSUDA, Daiki**; 3855 Elijah Court, Unit
728, San Diego, CA 92130 (US). **KHOSHNEJAD,
Makan**; 1629 Briar Hill Rd., Gladwyne, PA 19035 (US).
ZHANG, Yan; 14382 Powary Road, Poway, CA 92064
(US). **NGUYEN, Duy**; 9880 Campus Point Drive, Suite
220, San Diego, CA 92121 (US). **YONG, Qian-chen**; 9880
Campus Point Drive, Suite 220, San Diego, CA 92121 (US).
AGHAJANIAN, Haig; 9 Honey Locust Court, Lafayette
Hill, PA 19444 (US). **BOT, Adrian, Ion**; 3090 Franklin
Canyon Drive, Beverly Hills, CA 90210 (US). **KARMALI,
Priya, Prakash**; 11438 Cypress Canyon Park Drive, San
Diego, CA 92131 (US). **SIEVERS, Stuart, Aaron**; 15467
Lemay Street, Van Nuys, CA 91406 (US).

(74) Agent: **TA, My, Chau**; McDonnell Boehnen Hulbert &
Berghoff LLP, 300 South Wacker Drive, Chicago, IL 60606
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning authorization of rectification
of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(48) Date of publication of this corrected version:
10 July 2025 (10.07.2025)

(15) Information about Correction:
see Notice of 10 July 2025 (10.07.2025)

WO 2025/096878 A9

(54) Title: RNA FOR IN VIVO TRANSFECTION WITH INCREASED EXPRESSION

(57) Abstract: This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5' untranslated region (UTR) and 3' UTR, particular 3' UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.